Current treatment for SSc is limited (Steen, 2001). For most disease manifestations treatment is primarily symptomatic and generally inadequate. The exception is renal disease, scleroderma renal crisis, once a major cause of mortality in SSc patients, can often be treated successfully with angiotensin converting enzyme inhibitors. Pulmonary complications now represent the major cause of mortality. Cyclophosphamide provides some benefit in patients with interstitial lung disease (ILD), the most lethal complication of SSc. However, the effect of this agent on SSc-associated ILD is modest and transient (Tashkin et al., 2006; Tashkin et al., 2007). Pulmonary arterial hypertension (PAH) also leads to considerable mortality in SSc patients. PAH may respond to vasodilators such as epoprostanol and bosentan, but frequently responses are incomplete and mortality still high(Badesch et al., 2009) . Bowel hypomotility also leads to considerable morbidity and sometimes mortality. Esophageal hypomotility is treated, frequently without success, with pro-motility and acid-blocking agents. Dysmotility of the lower bowel and its complications are even more difficult to treat with pro-motility agents providing modest relief in some patients and antibiotics helping in cases of small bowel overgrowth. Thus there are limited therapeutic alternatives for SSc patients faced with progressive lung or bowel disease.